New treatment for acute hepatic porphyria
The U.S. Food and Drug Administration (FDA) recently granted approval to Alnylam Pharmaceuticals’ givosiran (Givlaari), a new treatment for adult patients with acute hepatic porphyria (AHP). (more…)
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.
